AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS

氨基硫醇治疗肾病性胱氨酸贮积症

• 批准号: 6244626
• 负责人: JESS G THOENE
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244626
• 关键词: child (0-11); clinical research; clinical trials; cysteamine; cystinosis; drug metabolism; drug screening /evaluation; human subject; human therapy evaluation; kidney disorder chemotherapy; metabolism disorder chemotherapy; pediatric pharmacology; pharmacokinetics

Cysteamine therapy of nephropathic cystinosis received new drug approval from the FDA on August 15, 1994. The clinical investigation leading to new drug approval was initiated by Dr. Thoene at the University of Michigan in 1978. At this time the above referenced protocol is maintained to assist those children who cannot tolerate the marketed version which is prepared only in 50 mg and 200 mg capsules.

肾病性囊肿病的cysteamine治疗获得了新药物批准 从1994年8月15日从FDA开始。临床调查导致 新药批准是由大学的Thoene博士发起的 1978年密歇根州。目前上述参考方案是 维持帮助那些无法容忍市场的孩子 仅以50毫克和200毫克胶囊制备的版本。